Phase IB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy, Carboplatin, and Everolimus in Patients With Locally Advanced Esophageal Cancer

Nabil F. Saba,Seth D. Force,Charley Staley,Felix G. Fernandez,Field F. Willingham,Allan Pickens,Kenneth Cardona,Zhengjia Chen,Laura Williams Goff,Dana Backlund Cardin,Eric S. Lambright,Jon Nesbitt,Alyssa M. Krasinskas,Kristin A. Higgins,R. Donald Harvey,Taofeek K. Owonikoko,Suresh S. Ramalingam,Dong M. Shin,Jonathan J. Beitler,Bassel F. El-Rayes,Safia N. Salaria,Wael El–Rifai,Jerome C. Landry,Anuradha Bapsi Chakravarthy

Phase IB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy, Carboplatin, and Everolimus in Patients With Locally Advanced Esophageal Cancer

2019

Purpose:Preclinical studies have shown synergy between everolimus, an mTOR inhibitor, radiation, and platinum agents. We conducted a phase IB trial to determine the recommended phase II dose of everolimus with carboplatin and radiation.Materials and Methods:Patients with stage II/III esophageal canc

Keywords:

Pathology
Oncology
Radiation therapy
Carboplatin
Everolimus
Esophageal cancer
Induction chemotherapy
Medicine
Internal medicine
in patient
locally advanced
stage ii

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations